Verdiva Bio is committed to developing next-generation therapies to help people living with obesity, cardiometabolic disorders, and related complications achieve better outcomes via more patient-friendly therapeutic options.
Verdiva Bio has raised €399M across 1 funding round from 7 investors, most recently a Series A round in Jan 2025. Based in London, UK; active in Healthtech. Data as of 7 Aug 2026.
Timing: in window vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2025-01-10 | Series A | €399M |
| Forbion,General Atlantic,Lilly Asia Ventures,Logos Capital,LYFE Capital,OrbiMed+1 more |
| View deal → |
